Document is current
Any future updates will be listed below
-
Authors
Oura, Mitsuaki https://orcid.org/0000-0002-4907-4647
Oguro, Fumiya https://orcid.org/0000-0003-4739-7589
Agatsuma, Nobukazu https://orcid.org/0000-0002-4605-5985
Imamaki, Hirotaka
Nishikawa, Yoshitaka https://orcid.org/0000-0003-3313-1990
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP22K17367)
- License Information
-
More Information
Article History
Received: 23 January 2023
Accepted: 9 May 2023
First Online: 19 May 2023
Declarations
:
: HI received lecture fees outside the submitted work from Kyowa Kirin Company, Limited, Kowa Co., Ltd, AstraZeneca K.K., Taisho Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Novo Nordisk A/S, Sumitomo Pharma Co., Ltd. All other authors have no conflicts of interest to disclose.
: This study was entirely based on an anonymized open database, and thus, ethical approval was not required. This study was conducted in accordance with the terms of use of the Japanese Adverse Drug Event Report database provided by Pharmaceuticals and Medical Devices Agency.
: This study was based on an anonymized database that can be widely downloaded by anyone, and consent to participate was not required.
